It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma-Reference-Cited by-同舟云学术

It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma

Published:2017-02-01 Issue:4 Volume:35 Page:475-477
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Elimova Elena¹,Janjigian Yelena Y.¹,Mulcahy Mary¹,Catenacci Daniel V.¹,Blum Mariela A.¹,Almhanna Khaldoun¹,Hecht J. Randolph¹,Ajani Jaffer A.¹

Affiliation:

1. Elena Elimova, University of Texas MD Anderson Cancer Center, Houston, TX; Yelena Y. Janjigian, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Mary Mulcahy, Feinberg School of Medicine, Lurie Comprehensive Cancer Center, Chicago, IL; Daniel V. Catenacci, University of Chicago, Chicago, IL; Mariela A. Blum, University of Texas MD Anderson Cancer Center, Houston, TX; Khaldoun Almhanna, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; J. Randolph Hecht...

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.69.7276

Reference16 articles.

1. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers

2. Cunningham D, Alderson D, Nankivell MG, et al: Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK 02/010). J Clin Oncol 32:5s, 2014 (suppl; abstr 4014)

3. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

4. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

5. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy;Annals of Surgical Oncology;2024-07-24

2. Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy;The Oncologist;2024-07-24

3. Predictive value of peripheral blood leukocytes-based methylation of Long non-coding RNA MALAT1 and H19 in the chemotherapy effect and prognosis of gastric cancer;Translational Oncology;2024-06

4. BNIP3 and DAPK1 methylation in peripheral blood leucocytes are noninvasive biomarkers for gastric cancer;Gene;2024-03

5. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol;BMJ Open;2024-02